Table 3 HR and 95%CI for multivariate-adjusted Analysis of the ApoB/apoA1 ratio, TC/HDL-c or Framingham Risk Score to Long-term Clinical Outcomes
Quartiles of plasma apoB/apoAI ratios | 1-SD Increasing of Variablea | ||||
ApoB/apoA1 ratio | Q1(n = 567) | Q2(n = 568) | Q3(n = 565) | Q4(n = 562) | |
 Model 1 | 1 | 1.14 (0.66–1.88) | 1.12 (0.65–1.94) | 1.75 (1.09–2.95) | 1.55 (0.26–1.91) |
 Model 2 | 1 | 1.15 (0.68–1.97) | 1.13 (0.65–1.97) | 1.91 (1.09–2.89) | 1.57 (1.28–1.93) |
 Model 3 | 1 | 1.25 (0.69–2.23) | 1.31 (0.73–2.35) | 1.92 (1.10–3.13) | 1.59 (1.29–1.96) |
Quartiles of TC/HDL-c | |||||
TC/HDL-c | Q1(n = 566) | Q2(n = 568) | Q3(n = 563) | Q4(n = 565) |  |
 Model 1 | 1 | 0.82 (0.52–1.32) | 1.09 (0.70–1.69) | 1.21 (0.78–1.87) | 1.04 (0.89–1.23) |
 Model 2 | 1 | 0.78 (0.48–1.25) | 1.03 (0.67–1.60) | 1.17 (0.76–1.81) | 1.03 (0.87–1.23) |
 Model 3 | 1 | 0.90 (0.52–1.56) | 1.16 (0.64–2.11) | 1.27 (0.56–2.89) | 1.02 (0.85–1.22) |
Quartiles of Framingham Risk Score | |||||
Framingham Risk Score | Q1(n = 457) | Q2(n = 721) | Q3(n = 603) | Q4(n = 481) |  |
 Model 1 | 1 | 1.04 (0.63–1.70) | 1.00 (0.60–1.67) | 1.60 (0.98–2.59) | 1.04 (0.98–1.09) |
 Model 2 | 1 | 1.37 (0.80–2.36) | 1.56 (0.84–2.56) | 2.12 (1.06–3.02) | 1.11 (1.04–1.18) |
 Model 3 | 1 | 1.34 (0.75–2.4) | 1.31 (0.67–2.57) | 2.20 (1.08–3.56) | 1.08 (1.01–1.15) |